[Indications for the use of tactivin in the combined treatment of phlegmons of the maxillofacial area].

The effects of subcutaneous and endolymphatic tactivin (in doses of 1 ml of 0.01% solution daily for 7 days) on clinical and immunological parameters were studied in patients with acute inflammations in the maxillofacial area, running a normo-, hypo-, and hyperergic course. Tactivin accelerated the arrest of inflammatory process and improved the patients' status, particularly so in cases with the hypo- and hyperergic inflammations. The key role in the mechanism of the drug action is played by increase of the immunoregulatory index, which reflects the increasing resistance of the body.